Ayahuasca, a psychoactive Amazonian brew containing DMT and harmala alkaloids, is increasingly used worldwide in traditional and neo-shamanic settings. A review of existing literature and original qualitative data from a large cross-sectional study of ayahuasca drinkers proposes a model of five key psychotherapeutic processes inherent to the experience: somatic effects, introspection and emotional processing, increased self-connection, increased spiritual connection, and gaining insights and new perspectives. These processes, facilitated by neurobiological effects, are argued to lead to beneficial mental health and wellbeing outcomes. The model highlights differences from other classic psychedelics and implications for therapeutic use.
Serotonergic psychedelics, including psilocybin, ayahuasca, LSD, and MDMA, show promise for treating mood disorders and PTSD, often combined with psychotherapy. Psilocybin with psychological support has been effective for depression, including treatment-resistant cases, in randomized placebo-controlled trials. LSD has shown anxiolytic effects, and MDMA has Phase III evidence for PTSD. Microdosing has not been found to improve mood in a controlled trial. Challenges remain with blinding, small sample sizes, and lack of definitive Phase III studies (except MDMA for PTSD). Further research into novel formulations, pharmacogenomics, microbiome interactions, and inflammatory pathways is needed.
Ayahuasca, a psychoactive Amazonian brew containing harmala alkaloids and DMT, is increasingly used globally in traditional and neo-shamanic settings. This paper reviews existing literature and original data from the Global Ayahuasca Project, the largest cross-sectional study of ayahuasca drinkers, to propose a model of psychotherapeutic processes leading to mental health benefits. The model identifies five key processes: somatic effects; introspection and emotional processing; increased self-connection, value, and love; increased spiritual connection; and gaining insights and new perspectives. Differences from other classic psychedelics are noted, and the model aims to improve therapeutic use and optimize clinical treatment models.